ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2011

Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab.

Xabier Garcia-Albeniz et al.PubMed ↗Publisher ↗

No numbers read from the abstract.